Daxor Corp (Daxor) is a biotechnology company, which offers original medical equipment for medical personnel. The company manufactures blood volume analyzers. Its flagship product, BVA-100 blood volume analyzer is an instrument to measure human blood volume. The product is used in conjunction with Volumex, a diagnostic radiopharmaceutical containing iodinated I 131 albumins. It finds application in a range of medical and surgical conditions which includes congestive heart failure, intensive care unit medicine, critical care medicine, syncope, kidney failure, hypertension, renal failure, red blood cell abnormalities, hyponatremia and other conditions. The company offers its product to hospitals, clinics, and physicians. Daxor is headquartered in Oak Ridge, Tennessee, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Report Scope
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Daxor Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Daxor Corp Company Overview
- Daxor Corp Company Snapshot
- Daxor Corp Pipeline Products and Ongoing Clinical Trials Overview
- Daxor Corp - Pipeline Analysis Overview
- Business Description
- Daxor Corp - Key Facts
- Daxor Corp - Major Products and Services
- Daxor Corp Pipeline Products by Development Stage
- Daxor Corp Pipeline Products Overview
- BVA-100 - Acute Decompensated Heart Failure
- BVA-100 - Acute Decompensated Heart Failure Product Overview
- BVA-100 - POTS
- BVA-100 - POTS Product Overview
- BVA-100 Combat Casualty Care
- BVA-100 Combat Casualty Care Product Overview
- BVA-100 Glomerular Filtration Rate
- BVA-100 Glomerular Filtration Rate Product Overview
- Clinical Decision Support Software
- Clinical Decision Support Software Product Overview
- Max-200
- Max-200 Product Overview
- Point-Of-Care Diagnostic Device - Heart Failure
- Point-Of-Care Diagnostic Device - Heart Failure Product Overview
- Sepsis FLO (Sepsis Fluid Optimizer)
- Sepsis FLO (Sepsis Fluid Optimizer) Product Overview
- Total Body Albumin Algorithm
- Total Body Albumin Algorithm Product Overview
- Daxor Corp - Key Competitors
- Daxor Corp - Key Employees
- Daxor Corp - Key Employee Biographies
- Daxor Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Daxor Corp, Recent Developments
- Mar 26, 2026: Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
- Mar 17, 2026: Daxor to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
- Mar 10, 2026: Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
- Mar 03, 2026: Daxor CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
- Nov 25, 2025: Daxor Fuels Growth With Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
- Nov 25, 2025: Daxor Expands BVA Platform to Three Facilities and Deploys New Analyzer
- Oct 15, 2025: Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
- Sep 30, 2025: Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
- Sep 23, 2025: Daxor Corporation Introduces Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
- Sep 23, 2025: Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Daxor Corp Pipeline Products and Ongoing Clinical Trials Overview
- Daxor Corp Pipeline Products by Equipment Type
- Daxor Corp Pipeline Products by Indication
- Daxor Corp, Key Facts
- Daxor Corp, Major Products and Services
- Daxor Corp Number of Pipeline Products by Development Stage
- Daxor Corp Pipeline Products Summary by Development Stage
- BVA-100 - Acute Decompensated Heart Failure - Product Status
- BVA-100 - Acute Decompensated Heart Failure - Product Description
- BVA-100 - POTS - Product Status
- BVA-100 - POTS - Product Description
- BVA-100 Combat Casualty Care - Product Status
- BVA-100 Combat Casualty Care - Product Description
- BVA-100 Glomerular Filtration Rate - Product Status
- BVA-100 Glomerular Filtration Rate - Product Description
- Clinical Decision Support Software - Product Status
- Clinical Decision Support Software - Product Description
- Max-200 - Product Status
- Max-200 - Product Description
- Point-Of-Care Diagnostic Device - Heart Failure - Product Status
- Point-Of-Care Diagnostic Device - Heart Failure - Product Description
- Sepsis FLO (Sepsis Fluid Optimizer) - Product Status
- Sepsis FLO (Sepsis Fluid Optimizer) - Product Description
- Total Body Albumin Algorithm - Product Status
- Total Body Albumin Algorithm - Product Description
- Daxor Corp, Key Employees
- Daxor Corp, Key Employee Biographies
- Daxor Corp, Subsidiaries
- Glossary
- Daxor Corp Pipeline Products by Equipment Type
- Daxor Corp Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Siemens Healthineers AG
- Pacific Reproductive Center
- Hema Care Corp.
- Genetics & IVF Institute
- California Cryobank LLC
